Abstract
Introduction/Purpose
Mechanical thrombectomy (MT) for acute ischemic stroke (IS) can be performed also in patients on anticoagulation therapy (AT); however, sufficient and reliable data about safety and efficacy of MT are still missing. Thus, we aimed to compare these parameters between patients treated on AT and without AT.
Materials and Methods
All consecutive IS patients treated with MT using stent retrievers were included in the retrospective analysis. Neurological deficit was scored using National Institutes of Health Stroke Scale (NIHSS) and 90-day clinical outcome using modified Rankin scale with a score 0–2 for good outcome. Recanalization was rated using Thrombolysis in Cerebral Infarction (TICI) scale. Symptomatic intracerebral hemorrhage (SICH) was assessed according to the SITS-MOST criteria.
Results
Out of 703 patients treated with MT, 88 (12.5%) patients (46% males, mean age 75.5 ± 11.8 years) were on AT with an admission median NIHSS of 17 points. Recanalization (TICI 2b-3) was achieved in 80% and complete (TICI 3) in 65% of patients on AT and in 80 and 65% of patients without AT (p—1.000). SICH after MT was detected in 9% of AT and 5% of non-AT patients (p—0.136). Good outcome was present in 36% of AT patients (p—0.03). AT patients with poor outcome had more frequently atrial fibrillation (93%, p—0.005), higher admission NIHSS (17, p—0.004) and higher rate of SICH (14.5%, p—0.047).
Conclusion
MT seems to be safe also in patients on AT. Poor outcome may be related to higher admission NIHSS, higher rate of SICH and presence of atrial fibrillation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, American Heart Association Stroke Council, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:3020–35. https://doi.org/10.1161/STR.0000000000000074.
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, for the DAWN Trial Investigators, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11–21. https://doi.org/10.1056/nejmoa1706442.
Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, for the DEFUSE 3 Investigators, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018. https://doi.org/10.1056/nejmoa1713973 (Epub 2018 Jan 24).
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. https://doi.org/10.1056/NEJMoa0905561.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. https://doi.org/10.1056/NEJMoa1009638.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. https://doi.org/10.1056/NEJMoa1107039.
Sjögren V, Byström B, Renlund H, Svensson PJ, Oldgren J, Norrving B, et al. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: a retrospective register study. PLoS ONE. 2017;12(7):e0181000. https://doi.org/10.1371/journal.pone.0181000.
Li W-H, Huang D, Chiang C-E, Lau C-P, Tse H-F, Chan EW, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. Clin Cardiol. 2017;40:222–9. https://doi.org/10.1002/clc.22649.
Berkhemer OA, Fransen PPS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.
Goyal M, Demchuk AM, Menon BK, for the ESCAPE Trial Investigators, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30.
Saver JL, Goyal M, Bonafe A, for the STAR Investigators, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285–95.
Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296–306.
Campbell BC, Mitchel PJ, Kleinig HM, et al. Endovascular treatment for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–18.
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, HERMES collaborators, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723–31. https://doi.org/10.1016/S0140-6736(16)00163-X.
Higashida RT, Furlan AJ. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003;34:109–37.
Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39:3316–22. https://doi.org/10.1161/strokeaha.107.510768.
Liang J, Liu W, Sun J, Gu X, Ma Q, Tong W. Analysis of the risk factors for the short-term prognosis of acute ischemic stroke. Int J Clin Exp Med. 2015;8:21915–24 (eCollection 2015).
Benavente L, Larrosa D, García-Cabo C, Pérez ÁI, Rico M, Vega P, et al. Safety and efficacy of mechanical thrombectomy in acute ischemic stroke of anticoagulated patients—a prospective observational study. J Stroke Cerebrovasc Dis. 2016;25:2093–8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.06.006.
Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol. 2012;11:1066–81. https://doi.org/10.1016/S1474-4422(12)70258-2.
Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20. https://doi.org/10.1056/NEJMoa1502000.
Diener HC, Kleinschnitz C. Non-vitamin K oral anticoagulants in stroke patients: practical issues. J Stroke. 2016;18:138–45. https://doi.org/10.5853/jos.2016.00157.
Acknowledgements
The study was supported by the grant of the IGA LF UP_010_2017, IGA-KZ-2016-1-2 and partially by the grant of Ministry of Health Czech Republic, No. 17-30101A.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Černík, D., Šaňák, D., Divišová, P. et al. Mechanical Thrombectomy in Patients with Acute Ischemic Stroke on Anticoagulation Therapy. Cardiovasc Intervent Radiol 41, 706–711 (2018). https://doi.org/10.1007/s00270-018-1902-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-018-1902-7